Dr. Yuri Maricich joins PKG Health as its Chief Medical & Scientific Officer
August 27, 2023
PKG Health is pleased to announce that Dr. Yuri Maricich has joined the leadership team as Chief Medical & Scientific Officer.
Dr. Maricich is a licensed physician-scientist, therapeutic developer, investor, and strategist. He brings a unique blend of medical practice, biotech, and digital health experience and expertise. Dr. Maricich has a history of improving our healthcare ecosystem by investing, advising, and leading innovative firms.
“Dr. Maricich’s expertise and unique experience in precision medicine and digital health is a perfect fit as we enter our next phase of growth,” said Zach Henderson, CEO of PKG Health. “In addition to leading our Clinical Advisory Board (CAB), Dr. Maricich will help guide our DTx strategy with our Life Science partners.”
In addition to clinical practice, he has led successful teams + programs at biotech & healthcare firms including Xdynia (acquired Cavion), Cavion (acq Jazz Pharmaceuticals), Corixa (acq GlaxoSmithKline), Pear Therapeutics (public offering) where Dr. Maricich pioneered the 1st three FDA market authorized prescription digital therapeutics through clinical development, regulatory approval, and reimbursement across multiple commercial and Medicaid health plans.
Dr. Maricich said “I’m pleased to work with the Global Kinetics / PKG team as they expand the use and impact of the PKG in patients with movement disorders.” The PKG is the only FDA authorized software-in-medical-device (SiMD) that has demonstrated improvement measurement and clinical outcomes in patients with Parkinson’s disease and other movement disorders. “Patients with movement disorders, including Parkinson’s disease have significant unmet medical needs. Existing treatment options, particularly carbidopa/levodapa are limited by off-times and imprecision in use. Tens of thousands of patients and their clinicians have used the PKG to produce improved outcomes as well as researchers and pharma companies developing novel therapeutics. I am excited to work together with the PKG team to further work to transform the care of patients with movement disorders.”
Dr. Maricich is a Venture Partner at Angelini Ventures and provides Chief Medical Officer and advisory services to a portfolio of biotech, digital health, and precision-medicine firms. He completed his education and training at Harvard University, University of Washington, University of Notre Dame and the University of Virginia.
PKG Health leverages the world’s largest body of clinical evidence in neurology, to create and deliver precision medicine by accelerating the research, approval and adoption of treatments. Because we believe every person with a neurological condition deserves to live their best life every day. For more information on PKG Health, please visit us at www.pkghealth.com.
